Royalty Pharma's Q4 results show portfolio receipts of $742 million and operating cash flow of $678 million. Read why RPRX ...

Royalty Receipts grew 12% to $729 million in the fourth quarter and 13% to $2,771 million for full year 2024, driven by strong performance from ...

Royalty Pharma (RPRX) expects 2025 Portfolio Receipts to be between $2,900 million and $3,050 million, representing expected growth of 4% to ...

Pablo Legorreta, CEO, highlighted strong 2024 performance, with Portfolio Receipts reaching $2.8 billion, at the high end of guidance and representing 13% growth in Royalty Receipts. He noted this ...

ICON plc, a clinical research organization, expanded its portfolio of artificial intelligence (AI) tools that aim to deliver efficiencies across the clinical trial process, including study startup, ...

and portfolio pricing. Given the evolving pressures in the pharmaceutical industry, manufacturers must take a proactive approach to navigating the challenges ahead. First and foremost, they should ...

Matt Barnes, EVP, President of Nxera Pharma UK and Head of R&D, commented: “It is extremely encouraging to see the progress being made by Neurocrine across this exciting portfolio of muscarinic ...